AOD-9604 in Children Under 12: What Parents and Clinicians Need to Know About Developmental Impact

What Is AOD-9604 and Why Does It Appear in Pediatric Conversations?

AOD-9604 is a 16-amino-acid synthetic peptide derived from the C-terminal end of human growth hormone. It was originally developed by Monash University and later licensed to Metabolic Pharmaceuticals to treat adult obesity. The peptide reached Phase 3 clinical evaluation in adults but failed to meet its primary endpoint in the key trial.

Despite that failure, AOD-9604 circulates widely in the compounding pharmacy market. Parents of children with growth concerns, obesity, or metabolic conditions sometimes encounter it in online communities and ask whether it could help their child.

The Chemistry Behind the Fragment

Full-length recombinant human growth hormone (rhGH) contains 191 amino acids. AOD-9604 isolates residues 176 to 191, the region hypothesized to mediate fat-cell lipolysis. Because this fragment does not include the receptor-binding domain responsible for IGF-1 stimulation, it was marketed as carrying fewer of the side effects associated with full-length GH, such as insulin resistance and acromegaloid features [1].

That mechanistic argument was relevant to the adult obesity indication. It does not translate safely to children, whose growth depends on a precisely timed interplay of GH, IGF-1, insulin, sex steroids, and thyroid hormone.

Why Pediatric Use Comes Up at All

Pediatric endocrinologists report that families of children with Prader-Willi syndrome, short stature, and early-onset obesity occasionally present asking about peptide therapies they have read about online. AOD-9604 appears in these conversations partly because its mechanism sounds less aggressive than full-dose rhGH, and partly because compounding pharmacies do not require a pediatric-specific prescription label. Neither of these facts makes it safe or appropriate for children under 12 [2].

FDA Regulatory Status: No Approval Means No Pediatric Approval

AOD-9604 holds no FDA-approved new drug application (NDA) or biologics license application (BLA) for any indication. The FDA granted AOD-9604 Generally Recognized as Safe (GRAS) status as a food ingredient in 2014, but GRAS status applies only to the specific use evaluated (a functional food ingredient) and cannot be extrapolated to injectable or oral therapeutic dosing in children [3].

GRAS Status Does Not Equal Therapeutic Safety

The FDA's GRAS pathway evaluates a substance for use in food at defined concentrations. It does not assess pharmacodynamic effects, receptor interactions, or long-term developmental consequences. Applying a GRAS determination to a clinical decision about a child's endocrine system is scientifically unsound.

The agency's own guidance on pediatric drug development, the Pediatric Research Equity Act (PREA), requires that sponsors study drugs in relevant pediatric subpopulations before marketing to children [4]. AOD-9604 has never been submitted under PREA. No pediatric pharmacokinetic data, no pediatric safety data, and no pediatric efficacy data exist in any FDA submission.

Compounding Pharmacies and the Regulatory Gap

Compounding pharmacies can prepare AOD-9604 under section 503A or 503B of the Federal Food, Drug, and Cosmetic Act. These sections allow limited compounding for specific patient needs but do not grant the compound approval status, and they do not require the pre-market safety testing that a full NDA demands [5]. A prescription written for a child under 12 for AOD-9604 would be entirely off-label, for a compound that has never cleared any therapeutic approval process.

The Pediatric Growth Axis: Why Timing Matters So Much

Children under 12 are in a biologically distinct phase of development. The hypothalamic-pituitary-somatotropic axis operates with different setpoints, pulse frequencies, and feedback sensitivities than in adults.

Growth Hormone Secretion Patterns in Prepubertal Children

Endogenous GH is released in discrete pulses, primarily during slow-wave sleep. In prepubertal children, mean overnight GH secretion rates are lower than in early puberty but are exquisitely sensitive to feedback disruption. The pituitary somatotrophs respond to growth hormone-releasing hormone (GHRH) and are suppressed by somatostatin. Any exogenous peptide with structural homology to GH, even a fragment, has the potential to interact with this feedback loop in ways that have not been characterized [6].

IGF-1 and the Epiphyseal Growth Plate

Linear growth in children depends on IGF-1 stimulating chondrocyte proliferation in epiphyseal growth plates. In the Growth Hormone Research Society's 2019 consensus guidelines, experts note: "Any intervention that alters GH or IGF-1 signaling in a growing child requires rigorous pre-clinical and clinical evaluation before use, given the irreversible nature of growth plate damage." [7]

AOD-9604 is reported to have minimal IGF-1-stimulating activity compared with full-length GH. That may sound reassuring, but it also means that if a family administers AOD-9604 hoping for growth-promoting effects, the child is being exposed to a peptide with no proven growth benefit and undefined risks to the very tissue it is supposed to spare.

Epiphyseal Plate Vulnerability

Growth plates in children under 12 are cartilaginous, active, and vulnerable. In animal studies using full-length GH analogs, supraphysiologic stimulation accelerated bone age and reduced final height potential. No analogous studies with AOD-9604 have been conducted in juvenile animals or pediatric humans [8]. The absence of data is not evidence of safety; it is simply an absence.

Available Clinical Trial Data: Adults Only

The most comprehensive human efficacy data for AOD-9604 come from a series of trials conducted by Metabolic Pharmaceuticals in the late 1990s and early 2000s.

Phase 2 Findings in Adults

A 12-week, double-blind, placebo-controlled dose-ranging study (N=300 adults with obesity) found that oral AOD-9604 at 1 mg/day produced modest weight loss compared with placebo, with a statistically significant difference of approximately 1.4 kg (P<0.05) [1]. Participants were adults aged 18 to 65 with BMI between 27 and 40. No children were enrolled.

Phase 3 Failure

The Phase 3 trial, also conducted in adults, failed to replicate the Phase 2 weight loss signal at 24 weeks. The company discontinued development for the obesity indication following that outcome. No Phase 3 data were ever published in a peer-reviewed journal, and the full dataset is not publicly available [9].

What This Means for Pediatric Risk Assessment

The adult trial dataset provides no pharmacokinetic parameters for children, no dose-scaling data, and no safety observations from any developing organism. Pediatric drug metabolism differs from adult metabolism in hepatic enzyme expression (particularly CYP3A4, CYP2D6, and glucuronidation pathways), renal clearance rates, and body-composition-dependent volume of distribution [10]. A dose considered low in a 90-kg adult could produce entirely different plasma concentrations in a 25-kg child.

Potential Developmental Risks: What Preclinical Science Suggests

Because human pediatric data do not exist, risk assessment relies on preclinical animal studies of GH-related peptides and on mechanistic reasoning.

Lipolytic Activity and Metabolic Development

The lipolytic mechanism attributed to AOD-9604 involves stimulation of beta-3 adrenergic receptors and inhibition of lipogenesis in adipose tissue [11]. In adults with excess adiposity, modest fat mobilization may be clinically beneficial. In a prepubertal child, adipose tissue serves developmental functions, including leptin production, which drives pubertal onset and hypothalamic maturation. Disrupting fat metabolism in this age group carries theoretical risks to pubertal timing that have not been studied.

Hypothalamic-Pituitary Feedback

Even if AOD-9604 has minimal GH receptor agonism, any peptide with GH structural homology may act as a partial agonist or competitive antagonist at GHRH receptor level or at downstream somatostatin feedback circuits. A 2018 review in the Journal of Clinical Endocrinology and Metabolism noted that "peptide fragments of GH can exhibit tissue-specific partial agonism that differs substantially from full-length GH, and these effects may be developmentally stage-dependent." [12]

Bone Density and Mineral Accretion

Peak bone mineral density accrual occurs between ages 9 and 18. Any substance altering GH signaling during this window could affect final bone density. The long-term consequences of reduced peak bone density are fracture risk in adulthood and increased rates of osteoporosis [13]. No AOD-9604 study has assessed bone mineral density in any population, adult or pediatric.

The table below summarizes the HealthRX clinical team's risk stratification framework for evaluating off-label peptide use in pediatric patients. This framework was developed internally to guide provider consultations and has not been published elsewhere.

| Risk Domain | AOD-9604 Evidence Grade | Clinical Action | |---|---|---| | Growth plate safety | No data (Grade D) | Contraindicate outside trial | | Hypothalamic feedback | Theoretical risk, no human data (Grade D) | Contraindicate outside trial | | Pubertal timing | No data (Grade D) | Contraindicate outside trial | | Bone mineral density | No data (Grade D) | Contraindicate outside trial | | Adult metabolic safety | Phase 2 data only (Grade C) | Acceptable for adults in clinical context | | Pediatric pharmacokinetics | No data (Grade D) | No dosing guidance possible |

Conditions Where Families Seek AOD-9604 for Children

Childhood Obesity

Childhood obesity affects approximately 19.7% of US children and adolescents aged 2 to 19 years, according to the CDC's 2017 to 2020 NHANES data [14]. Families dealing with a child's weight sometimes seek peptide therapies after conventional interventions have stalled.

For children aged 12 and older, semaglutide (Wegovy) received FDA approval in December 2022 based on the STEP TEENS trial, which demonstrated 16.1% mean BMI reduction at 68 weeks in adolescents aged 12 to 17 with obesity [15]. For children under 12, no GLP-1 receptor agonist or peptide therapy has received FDA approval for obesity. Lifestyle intervention remains the standard of care per the American Academy of Pediatrics' 2023 Clinical Practice Guidelines [16].

AOD-9604 is not an evidence-based alternative to approved treatments in any pediatric age group.

Short Stature and Growth Concerns

Recombinant human growth hormone (somatropin) is FDA-approved for pediatric growth hormone deficiency, Turner syndrome, Prader-Willi syndrome, chronic renal insufficiency, small for gestational age with failure to catch up, Noonan syndrome, SHOX gene deficiency, and idiopathic short stature [17]. These approvals are backed by controlled trial data in children.

AOD-9604 lacks any growth-promoting efficacy data even in adults. Its mechanism does not support growth promotion in a GH-deficient child. Families seeking alternatives to approved rhGH should discuss indications and risks with a pediatric endocrinologist rather than pursue compounded peptides.

Metabolic Syndrome in Children

The prevalence of metabolic syndrome in US children is estimated at 9.4% among those aged 12 to 19 with obesity, per NHANES analysis published in JAMA [18]. For children under 12, pharmacologic intervention for metabolic syndrome is not standard practice outside clinical trials. AOD-9604 has no data supporting its use in pediatric metabolic syndrome.

What Approved Pediatric Growth Hormone Therapy Looks Like

To contextualize the gap that AOD-9604 would need to fill, it helps to understand what properly studied pediatric GH therapy involves.

FDA-Approved rhGH Products

Somatropin products such as Norditropin, Genotropin, and Humatrope have accumulated decades of post-marketing safety data in children. The Pfizer International Growth Database (KIGS), which tracked over 83,000 children receiving GH therapy, provided longitudinal safety data on adverse events including glucose metabolism, slipped capital femoral epiphysis, intracranial hypertension, and cancer recurrence risk [19]. No comparable registry exists or is being developed for AOD-9604.

Monitoring Requirements for Approved GH Therapy

Children on approved rhGH require baseline and periodic monitoring of IGF-1 levels, thyroid function, fasting glucose, bone age X-rays, and clinical assessment for scoliosis. These monitoring requirements exist because even approved, well-studied GH therapy carries real risks that require active management. The idea that AOD-9604, an unapproved compound with no pediatric data, would carry fewer risks deserving less monitoring is not supported by any evidence.

Ethical and Legal Considerations for Clinicians

Prescribing AOD-9604 to a child under 12 raises serious ethical and legal questions under current US regulatory and medical ethics frameworks.

The Belmont Report's principle of beneficence requires that treatments offered to children have a reasonable expectation of benefit and an understood risk profile [20]. AOD-9604 in children under 12 meets neither criterion. The American Academy of Pediatrics' ethical guidelines on off-label prescribing state that off-label use is acceptable when supported by sound scientific evidence, but that it should not expose children to unquantified risks for unproven benefit [16].

A clinician who prescribes compounded AOD-9604 to a child under 12 for any indication would be operating entirely outside evidence-based guidelines, with no regulatory protection, no safety data, and no published dosing guidance. Medical liability exposure under these circumstances is substantial.

When Research Is the Right Path

If a researcher or clinician believes AOD-9604 may have a legitimate pediatric application, the appropriate path is through an Institutional Review Board (IRB)-approved clinical trial registered on ClinicalTrials.gov, with an IND (Investigational New Drug) application filed with the FDA under 21 CFR Part 312 [21]. As of January 2025, no such trial is listed on ClinicalTrials.gov for AOD-9604 in pediatric populations.

Parents who wish to access experimental treatments for their children may find resources through the FDA's Expanded Access program, which requires a treating physician to submit an IND application and obtain IRB approval. This pathway exists precisely to protect children from unregulated exposure to unapproved compounds [22].